NO314550B1 - Fremgangsmåte for fremstilling av et mutant herpesvirus - Google Patents
Fremgangsmåte for fremstilling av et mutant herpesvirus Download PDFInfo
- Publication number
- NO314550B1 NO314550B1 NO19931057A NO931057A NO314550B1 NO 314550 B1 NO314550 B1 NO 314550B1 NO 19931057 A NO19931057 A NO 19931057A NO 931057 A NO931057 A NO 931057A NO 314550 B1 NO314550 B1 NO 314550B1
- Authority
- NO
- Norway
- Prior art keywords
- virus
- gene
- expression system
- mutant
- corresponding expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 31
- 241001529453 unidentified herpesvirus Species 0.000 title claims description 10
- 241000700605 Viruses Species 0.000 claims abstract description 165
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 97
- 229960005486 vaccine Drugs 0.000 claims abstract description 40
- 208000015181 infectious disease Diseases 0.000 claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 230000002458 infectious effect Effects 0.000 claims abstract description 17
- 230000002950 deficient Effects 0.000 claims abstract description 9
- 108700005077 Viral Genes Proteins 0.000 claims abstract description 8
- 230000007547 defect Effects 0.000 claims abstract description 8
- 241000700584 Simplexvirus Species 0.000 claims description 30
- 230000003612 virological effect Effects 0.000 claims description 19
- 101150055782 gH gene Proteins 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 108090000288 Glycoproteins Proteins 0.000 claims description 10
- 102000003886 Glycoproteins Human genes 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 31
- 239000013598 vector Substances 0.000 abstract description 11
- 230000002163 immunogen Effects 0.000 abstract description 10
- 230000001717 pathogenic effect Effects 0.000 abstract description 9
- 244000052769 pathogen Species 0.000 abstract description 6
- 241000894007 species Species 0.000 abstract description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 73
- 239000013612 plasmid Substances 0.000 description 37
- 108020004414 DNA Proteins 0.000 description 25
- 239000012634 fragment Substances 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000002238 attenuated effect Effects 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 108700039887 Essential Genes Proteins 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 10
- 241000701022 Cytomegalovirus Species 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 108700002232 Immediate-Early Genes Proteins 0.000 description 6
- 241000700618 Vaccinia virus Species 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 208000032420 Latent Infection Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 5
- 210000000609 ganglia Anatomy 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000007969 cellular immunity Effects 0.000 description 4
- 108700004025 env Genes Proteins 0.000 description 4
- 101150030339 env gene Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229960000380 propiolactone Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101100296182 Caenorhabditis elegans paf-2 gene Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 101150036031 gD gene Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 241000700321 Herpes simplex virus (type 1 / strain SC16) Species 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 101800003344 Vaccinia growth factor Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 101150118163 h gene Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909020799A GB9020799D0 (en) | 1990-09-25 | 1990-09-25 | Viral vaccines |
| GB919104903A GB9104903D0 (en) | 1991-03-08 | 1991-03-08 | Viral vaccines |
| PCT/GB1991/001632 WO1992005263A1 (en) | 1990-09-25 | 1991-09-23 | Viral defective vaccine produced by transcomplementing cell line |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO931057D0 NO931057D0 (no) | 1993-03-23 |
| NO931057L NO931057L (no) | 1993-05-03 |
| NO314550B1 true NO314550B1 (no) | 2003-04-07 |
Family
ID=26297693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19931057A NO314550B1 (no) | 1990-09-25 | 1993-03-23 | Fremgangsmåte for fremstilling av et mutant herpesvirus |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6541009B1 (ja) |
| EP (2) | EP0550553B1 (ja) |
| JP (1) | JP3895366B2 (ja) |
| KR (1) | KR100372934B1 (ja) |
| AT (1) | ATE194657T1 (ja) |
| AU (1) | AU658836B2 (ja) |
| BR (1) | BR9106879A (ja) |
| CA (1) | CA2091678C (ja) |
| DE (1) | DE69132311T2 (ja) |
| DK (1) | DK0550553T3 (ja) |
| ES (1) | ES2150416T3 (ja) |
| FI (1) | FI110438B (ja) |
| GB (1) | GB2263480B (ja) |
| GR (1) | GR3034484T3 (ja) |
| HK (1) | HK1001656A1 (ja) |
| MX (1) | MX9203717A (ja) |
| NO (1) | NO314550B1 (ja) |
| OA (1) | OA09777A (ja) |
| WO (1) | WO1992005263A1 (ja) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| WO1990010693A1 (en) * | 1989-03-08 | 1990-09-20 | Health Research, Inc. | Recombinant poxvirus host selection system |
| EP0550553B1 (en) | 1990-09-25 | 2000-07-12 | Cantab Pharmaceuticals Research Limited | Viral defective vaccine produced by transcomplementing cell line |
| US5837261A (en) * | 1990-09-25 | 1998-11-17 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
| US7374768B1 (en) | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
| US5665362A (en) * | 1990-09-25 | 1997-09-09 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
| DE69229390T2 (de) * | 1991-08-26 | 1999-11-11 | Immuno Ag, Wien | Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus |
| TW289731B (ja) * | 1992-07-09 | 1996-11-01 | Akzo Nv | |
| ATE288483T1 (de) * | 1992-07-30 | 2005-02-15 | Akzo Nobel Nv | Nicht-verbreitendes lebendes herpesvirusvakzin |
| US7223411B1 (en) * | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
| DE69332501T3 (de) * | 1992-07-31 | 2009-03-26 | The President And Fellows Of Harvard College, Cambridge | Herpesvirus impfstoffe |
| AU696336B2 (en) * | 1993-03-19 | 1998-09-10 | Cantab Pharmaceuticals Research Limited | Defective mutant non-retroviral virus (e.g. HSV) as vaccine |
| AU7192394A (en) * | 1993-07-19 | 1995-02-20 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| AU7263994A (en) * | 1993-08-06 | 1995-02-28 | Kai Juhani Ernst Krohn | Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses |
| EP0659885A1 (en) * | 1993-12-21 | 1995-06-28 | Akzo Nobel N.V. | Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity |
| AU694519B2 (en) * | 1994-04-29 | 1998-07-23 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
| US6156319A (en) * | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
| US5807557A (en) * | 1994-07-25 | 1998-09-15 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex |
| GB9415369D0 (en) * | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| GB9423663D0 (en) * | 1994-11-23 | 1995-01-11 | Cantab Pharma Res | Viral preparations, immunogens, and vaccines |
| ES2264136T3 (es) * | 1995-02-21 | 2006-12-16 | Cantab Pharmaceuticals Research Limited | Preparaciones virales, vectores, inmunogenos y sus vacunas. |
| JPH11502222A (ja) * | 1995-03-23 | 1999-02-23 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 遺伝子供給用ベクター |
| EP0828823A4 (en) * | 1995-06-01 | 1999-02-10 | Merck & Co Inc | HERPES SIMPLEX TYPE 1 VIRUS PROTEASE MUTANTS AND VECTORS THEREOF |
| EP0856062A2 (en) * | 1995-10-19 | 1998-08-05 | St. Jude Children's Research Hospital | Herpesvirus vectors and their uses |
| DE19709148C1 (de) * | 1997-03-06 | 1998-09-03 | Evotec Biosystems Gmbh | Verfahren zur Herstellung eines Impfstoffes gegen infektiöse Erreger |
| JP2001523103A (ja) | 1997-04-28 | 2001-11-20 | ローヌ−プーラン・ロレ・エス・アー | 腫瘍治療用血管形成アンタゴニストのアデノウイルスによる腫瘍内送達 |
| EP0884382A3 (en) * | 1997-06-10 | 2000-10-25 | Pfizer Products Inc. | Processes for preparation of marek's disease virus using continuous mammalian cell lines |
| US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
| GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| GB9808922D0 (en) | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
| US6225456B1 (en) | 1998-05-07 | 2001-05-01 | University Technololy Corporation | Ras suppressor SUR-5 |
| US6506889B1 (en) | 1998-05-19 | 2003-01-14 | University Technology Corporation | Ras suppressor SUR-8 and related compositions and methods |
| GB9816761D0 (en) | 1998-07-31 | 1998-09-30 | Phogen Limited | Herpesvirus preparations and their uses |
| US6399354B1 (en) | 1998-07-31 | 2002-06-04 | President And Fellows Of Harvard College | Replication-competent virus expressing a detectable fusion protein |
| WO2000034497A2 (en) * | 1998-12-09 | 2000-06-15 | The General Hospital Corporation | Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors |
| US6441156B1 (en) * | 1998-12-30 | 2002-08-27 | The United States Of America As Represented By The Department Of Health And Human Services | Calcium channel compositions and methods of use thereof |
| GB9927353D0 (en) * | 1999-11-19 | 2000-01-19 | Cantab Pharma Res | Virus preparation and use |
| GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
| AU5345901A (en) | 2000-04-13 | 2001-10-30 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
| EP2287191B1 (en) | 2000-05-10 | 2016-10-12 | Mayo Foundation For Medical Education And Research | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| ATE368750T1 (de) | 2000-09-14 | 2007-08-15 | Sinai School Medicine | Screening-verfahren zum identifizieren von g- proteinen und anderen verbindungen,die die phosphodiesterase (pde)-aktivität beeinflussen |
| US7060442B2 (en) | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
| DE60144198D1 (de) | 2000-12-28 | 2011-04-21 | Wyeth Llc | Rekombinantes schutzprotein aus streptococcus pneumoniae |
| ATE448793T1 (de) | 2001-03-02 | 2009-12-15 | Univ Rockefeller | Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens |
| US7803982B2 (en) | 2001-04-20 | 2010-09-28 | The Mount Sinai School Of Medicine Of New York University | T1R3 transgenic animals, cells and related methods |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| US7432057B2 (en) | 2004-01-30 | 2008-10-07 | Michigan State University | Genetic test for PSE-susceptible turkeys |
| GB0716992D0 (en) | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| US7604798B2 (en) | 2004-07-15 | 2009-10-20 | Northwestern University | Methods and compositions for importing nucleic acids into cell nuclei |
| AU2005274948B2 (en) | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| GB2421025A (en) * | 2004-12-09 | 2006-06-14 | Oxxon Therapeutics Ltd | HSV vaccination vectors |
| US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
| WO2007005898A2 (en) | 2005-07-05 | 2007-01-11 | Cornell Research Foundation, Inc. | Blocking leukocyte emigration and inflammation by interfering with cd99l2 |
| US20100008944A1 (en) * | 2005-07-29 | 2010-01-14 | President And Fellows Of Harvard College | Herpes simplex virus mutant and uses therefore |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| US8093043B2 (en) | 2008-06-04 | 2012-01-10 | New York University | β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis |
| EP2303319B1 (en) | 2008-06-20 | 2016-10-05 | Duke University | Compositions, methods and kits for eliciting an immune response |
| MX2010014358A (es) | 2008-06-20 | 2011-07-04 | Wyeth Llc | Composiciones y metodos de uso del orf1358 de cepas estreptococicas beta-hemoliticas. |
| JP2012508174A (ja) | 2008-11-05 | 2012-04-05 | ワイス・エルエルシー | β溶血性連鎖球菌（ＢＨＳ）疾患を予防するための多成分免疫原性組成物 |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| AU2011227050B2 (en) | 2010-03-19 | 2016-12-08 | University Of South Alabama | Methods and compositions for the treatment of cancer |
| AU2011294776B2 (en) | 2010-08-23 | 2016-02-04 | Wyeth Llc | Stable formulations of Neisseria meningitidis rLP2086 antigens |
| CA2809758C (en) | 2010-09-10 | 2021-07-13 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| WO2012135696A2 (en) | 2011-04-01 | 2012-10-04 | University Of South Alabama | Methods and compositions for the diagnosis, classification, and treatment of cancer |
| DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
| WO2013103401A1 (en) | 2012-01-06 | 2013-07-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
| EP4043029A1 (en) | 2012-03-09 | 2022-08-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| ES2685894T3 (es) | 2013-03-08 | 2018-10-15 | Pfizer Inc. | Polipéptidos de fusión inmunogénicos |
| WO2014164703A1 (en) | 2013-03-11 | 2014-10-09 | University Of Florida Research Foundation, Inc. | Delivery of card protein as therapy for occular inflammation |
| MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
| EP3888675A1 (en) | 2013-09-24 | 2021-10-06 | Duke University | Compositions, methods and kits for eliciting an immune response |
| EP3105311A1 (en) | 2014-02-10 | 2016-12-21 | Univercells NV | System, apparatus and method for biomolecules production |
| WO2015127094A1 (en) | 2014-02-19 | 2015-08-27 | University Of Florida Research Foundation, Inc. | Delivery of nrf2 as therapy for protection against reactive oxygen species |
| RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
| MX2019009011A (es) | 2017-01-31 | 2019-09-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos. |
| CN110603058A (zh) | 2017-05-15 | 2019-12-20 | 扬森疫苗与预防公司 | 含有病毒的稳定组合物 |
| KR102658198B1 (ko) | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스 함유 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| EP0213894A3 (en) * | 1985-08-23 | 1987-10-21 | Advanced Genetics Research Institute | Defective viral particle vaccines and methods for their use |
| US4996152A (en) * | 1987-12-04 | 1991-02-26 | The United States Of America, As Represented By The Secretary Of Agriculture | Avian herpesvirus amplicon as a eucaryotic expression vector |
| CN1038306A (zh) * | 1988-03-21 | 1989-12-27 | 维吉恩公司 | 重组反转录病毒 |
| CA2002839C (en) * | 1988-11-14 | 2000-10-10 | Neal S. Young | Parvovirus capsids |
| JP3140757B2 (ja) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用 |
| WO1990010693A1 (en) | 1989-03-08 | 1990-09-20 | Health Research, Inc. | Recombinant poxvirus host selection system |
| FR2663228A2 (fr) * | 1989-09-29 | 1991-12-20 | Agronomique Inst Nat Rech | Composition immunisante contre la maladie de newcastle et procede de preparation. |
| CA2039921A1 (en) * | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| EP0550553B1 (en) | 1990-09-25 | 2000-07-12 | Cantab Pharmaceuticals Research Limited | Viral defective vaccine produced by transcomplementing cell line |
| AU672359B2 (en) * | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| DE69332501T3 (de) | 1992-07-31 | 2009-03-26 | The President And Fellows Of Harvard College, Cambridge | Herpesvirus impfstoffe |
-
1991
- 1991-09-23 EP EP19910917033 patent/EP0550553B1/en not_active Expired - Lifetime
- 1991-09-23 ES ES91917033T patent/ES2150416T3/es not_active Expired - Lifetime
- 1991-09-23 AT AT91917033T patent/ATE194657T1/de not_active IP Right Cessation
- 1991-09-23 WO PCT/GB1991/001632 patent/WO1992005263A1/en active IP Right Grant
- 1991-09-23 KR KR1019930700913A patent/KR100372934B1/ko active
- 1991-09-23 JP JP51739991A patent/JP3895366B2/ja not_active Expired - Fee Related
- 1991-09-23 CA CA 2091678 patent/CA2091678C/en not_active Expired - Lifetime
- 1991-09-23 EP EP19990106514 patent/EP0953648A3/en not_active Withdrawn
- 1991-09-23 AU AU86489/91A patent/AU658836B2/en not_active Ceased
- 1991-09-23 BR BR9106879A patent/BR9106879A/pt not_active Application Discontinuation
- 1991-09-23 DK DK91917033T patent/DK0550553T3/da active
- 1991-09-23 DE DE69132311T patent/DE69132311T2/de not_active Expired - Lifetime
-
1992
- 1992-06-29 MX MX9203717A patent/MX9203717A/es unknown
-
1993
- 1993-03-23 NO NO19931057A patent/NO314550B1/no not_active IP Right Cessation
- 1993-03-23 GB GB9306044A patent/GB2263480B/en not_active Expired - Fee Related
- 1993-03-24 FI FI931309A patent/FI110438B/fi active
- 1993-03-25 OA OA60354A patent/OA09777A/en unknown
-
1995
- 1995-06-05 US US08/462,632 patent/US6541009B1/en not_active Expired - Fee Related
-
1998
- 1998-01-27 HK HK98100722A patent/HK1001656A1/xx not_active IP Right Cessation
-
2000
- 2000-09-26 GR GR20000402173T patent/GR3034484T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100372934B1 (ko) | 2003-12-24 |
| FI931309A0 (fi) | 1993-03-24 |
| GB9306044D0 (en) | 1993-06-02 |
| US6541009B1 (en) | 2003-04-01 |
| FI110438B (fi) | 2003-01-31 |
| MX9203717A (es) | 1992-09-01 |
| EP0953648A3 (en) | 2007-09-12 |
| NO931057L (no) | 1993-05-03 |
| CA2091678C (en) | 2003-04-22 |
| DE69132311D1 (de) | 2000-08-17 |
| BR9106879A (pt) | 1993-07-20 |
| ATE194657T1 (de) | 2000-07-15 |
| EP0550553B1 (en) | 2000-07-12 |
| AU8648991A (en) | 1992-04-15 |
| HK1001656A1 (en) | 1998-07-03 |
| FI931309A (fi) | 1993-03-24 |
| DE69132311T2 (de) | 2000-12-14 |
| EP0953648A2 (en) | 1999-11-03 |
| ES2150416T3 (es) | 2000-12-01 |
| JPH06504194A (ja) | 1994-05-19 |
| WO1992005263A1 (en) | 1992-04-02 |
| NO931057D0 (no) | 1993-03-23 |
| GR3034484T3 (en) | 2000-12-29 |
| EP0550553A1 (en) | 1993-07-14 |
| GB2263480A (en) | 1993-07-28 |
| JP3895366B2 (ja) | 2007-03-22 |
| AU658836B2 (en) | 1995-05-04 |
| GB2263480B (en) | 1994-07-20 |
| DK0550553T3 (da) | 2000-10-23 |
| OA09777A (en) | 1993-11-30 |
| CA2091678A1 (en) | 1992-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6541009B1 (en) | Viral vaccines | |
| US5665362A (en) | Viral vaccines | |
| Xiang et al. | A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier | |
| JP3602530B2 (ja) | 遺伝子操作したワクチン菌株 | |
| Rosenthal et al. | Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes | |
| Patel et al. | Isolation and characterization of herpes simplex virus type 1 mutants defective in the UL6 gene | |
| US5698202A (en) | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier | |
| US6573090B1 (en) | Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors | |
| NO833205L (no) | Fremgangsmaate for modifisering av et virus for vaksineformaal | |
| US5824318A (en) | Avirulent herpetic viruses useful as tumoricidal agents and vaccines | |
| WO1992003537A1 (en) | Self-assembling replication defective hybrid virus particles | |
| US11844833B2 (en) | Expression system for expressing herpesvirus glycoprotein complexes | |
| Watanabe et al. | Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector | |
| JP4044131B2 (ja) | ヘルペスウイルスワクチン | |
| Brehm et al. | Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more α-genes: ICP4, ICP27, ICP22, and ICP0 | |
| AU725557B2 (en) | Avirulent herpetic viruses useful as tumoricidal agents and vaccines | |
| US7374768B1 (en) | Viral vaccines | |
| RU2236256C2 (ru) | Вакцина, содержащая мутантный вирус герпеса | |
| CN1062601C (zh) | 病毒疫苗 | |
| Morghen et al. | Virus vectors for immunoprophylaxis | |
| WO2023245159A1 (en) | Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines | |
| US20020086035A1 (en) | Herpevirus replication defective mutants | |
| CZ127394A3 (en) | Replication-capable recombinant virus, process of obtaining thereof and vaccine composition | |
| Kessler et al. | Expression of the human immunodeficiency virus gag gene products by a replication-incompetent herpes simplex virus vector | |
| WO1996016164A1 (en) | Viral preparations, immunogens, and vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |